(Q39763075)

14 September 2017

title

Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410). (English)

1 reference

14 September 2017

Yu-Chen Cai

1

1 reference

14 September 2017

Yong Zou

2

1 reference

14 September 2017

Yan-Li Ye

3

1 reference

14 September 2017

Hong-Yi Sun

4

1 reference

14 September 2017

Quan-Guan Su

5

1 reference

14 September 2017

Zhi-Xin Wang

6

1 reference

14 September 2017

Zhao-Lei Zeng

7

1 reference

14 September 2017

Li-Jian Xian

8

1 reference

14 September 2017

publication date

11 December 2009

1 reference

Investigational New Drugs

14 September 2017

published in

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

2

1 reference

14 September 2017

page(s)

300-311

1 reference

Tumor angiogenesis: therapeutic implications

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Openings between defective endothelial cells explain tumor vessel leakiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Signaling angiogenesis via p42/p44 MAP kinase and hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Angiogenesis: the role of the microenvironment in flipping the switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

HIF-1 and tumor progression: pathophysiology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9366-X

Oxygen sensing and molecular adaptation to hypoxia

21 January 2018

1 reference

12 December 2020

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

1 reference

12 December 2020

Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation

1 reference

12 December 2020

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

1 reference

12 December 2020

Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins

1 reference

12 December 2020

Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center

1 reference

12 December 2020

Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer

1 reference

12 December 2020

Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.

1 reference

12 December 2020

Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy

1 reference

12 December 2020

Potent anti-metastatic activity of combretastatin-A4.

1 reference

12 December 2020

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.

1 reference

12 December 2020

Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

1 reference

12 December 2020

Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model

1 reference

12 December 2020

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

1 reference

12 December 2020

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

1 reference

12 December 2020

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) and its effect on angiogenesis

1 reference

12 December 2020

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

12 December 2020

Involvement of hypoxia-inducible factor 1 in human cancer

1 reference

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

12 December 2020

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

12 December 2020

Hypoxia-inducible factor 1: master regulator of O2 homeostasis

1 reference

12 December 2020

10.1007/S10637-009-9366-X

Identifiers

DOI

1 reference

14 September 2017

1 reference